M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.
Sara Bringhen,Mariella Genuardi,Davide Rossi,Roberto Ria,Alessandra Romano,Felicetto Ferrara,Nicola Di Renzo,Alida Dominietto,Alessandro Andriani,Rita Rizzi,Roberto Vallone,Giuseppe Mele,Sergio Storti,Luigi Podda,G Aitoro,Vincenzo Mettivier,Ombretta Annibali,Fausto Rossini,Patrizia Gentilini,Vincenzo Pavone,Nicola Giuliani,Anna Maria Rauco,Anna Baraldi,Antonio Capaldi,Filippo Gherlinzoni,Gianluca Gaidano,Mario Boccadoro,Antonio Palumbo +27 more
TL;DR: The weekly infusion of bortezomib significantly decreased incidence of PN, discontinuation rate and dose-reduction rate without significant reduction of PFS and correlation between PN and clinical outcome is presented at the meeting.
Journal ArticleDOI
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
S. Vincent Rajkumar,Patrizia Falco,Shaji Kumar,Angela Dispenzieri,Maria Teresa Petrucci,Morie A. Gertz,Mario Boccadoro,A. Keith Stewart,Antonio Palumbo +8 more
TL;DR: The goal of this retrospective study was to compare the efficacy and toxicity of lenalidomide–dexamethasone (len/dex) vs. melphalan–prednisone–lenalidomides (MPR) as upfront therapy for newly diagnosed elderly patients with myeloma.
Journal Article
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients.
Pietro Quaglino,Tiziana Nardò,Maria Teresa Fierro,Massimo Massaia,L. Orsucci,Paolo Fava,Federica Marenco,Elena Marra,Paola Savoia,Umberto Vitolo,Mario Boccadoro,Maria Grazia Bernengo +11 more
TL;DR: Patients with haematological malignancies have a higher incidence of adverse drug reactions with peculiar morphologic features and a lower incidence of common chronic dermatoses than patients referred for dermatological consultation by their general practitioner or other hospital services.
Journal ArticleDOI
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients
Sara Bringhen,Valeria Magarotto,Anna Marina Liberati,Angelo Belotti,Alessandra Larocca,Milena Gilestro,Francesca Bonello,Gianluca Gaidano,Paola Bertazzoni,Raffaella Stocchi,Rossella Ribolla,Chiara Di Sano,Francesca Patriarca,Roberto Passera,Lorenzo De Paoli,Stefania Oliva,Anna Maria Cafro,Pieter Sonneveld,Antonio Palumbo,Mario Boccadoro +19 more
TL;DR: This phase I/II study assessed for the first time weekly Carfilzomib plus Pomalidomide and low dose Dexamethasone combination for the treatment of RRMM and determined the maximum tolerated dose (MTD) of wKPd combination.
Journal ArticleDOI
Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m2 in Elderly Newly Diagnosed Patients: An Interim Analysis.
Antonio Palumbo,Ilaria Avonto,Francesca Patriarca,Claudia Crippa,Maria Teresa Petrucci,Fausto Rossini,Paolo Corradini,Anna Marina Liberati,Nicola Giuliani,Norbert Pescosta,Patrizia Falco,Alessandra Larocca,Paola Omedè,Massimo Offidani,Renato Fanin,Mario Boccadoro +15 more
TL;DR: PAD is an effective induction approach, it may improve autologous transplant results in selected elderly patients and tandem melphalan 100 mg/m2 followed by stem cell infusion is investigated in newly diagnosed patients aged 65–75 years.